A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Inclusion Criteria: * Chinese healthy subjects aged from 18 to 50 years (including the boundary value) * Normal vital signs, physical examinations, ECG, clinical laboratory tests and imageological examination results or abnormal with no clinical significance according to the doctor's judgment; * Body weight between 50-90kg and BMI between 19.0-26.0kg/m2 (including boundary value); Exclusion Criteria: * People who have previously used or participated in clinical trials of monoclonal antibody with the same target or dupilumab * People with a clear history of allergy and/or allergy to monoclonal antibodies of the same target /investigational drugs and their components. * People who have special dietary requirements or are unable to follow a uniform diet. * Dizzy blood, dizzy needle history. Blood donation \> 400 ml within 3 months or \> 200 ml within 4 weeks prior to screening, or planning to donate blood during the study. * Having participated in drug or device clinical trials within 3 months or 5 half-lives of other investigational drugs before the study administration.